₹10.31
−3.28%NSE close, 16 Nov 2026
−29.77%
Nectar Lifesciences is a small cap company, listed on NSE under the symbol NECLIFE. At ₹10.31 a share, the market values the whole company at ₹200 crore.
In FY26, it reported sales of ₹0 crore and a net loss of ₹293 crore.
The market values the company at 0.35 times its book value; its return on equity is -11.6% and it has almost no borrowings.
Promoters hold 51.84% of the shares. Foreign institutions hold 0.50%, and domestic institutions, mutual funds among them, 3.90%.
Over the past year the share price has fallen 26.4%, and it is 54.0% below its 52-week high.
₹ crore. Consolidated figures.
The financial results for the period ended September 30, 2026.
With copy of minutes of Annual General Meeting held on September 18, 2026
Please find attached herewith Revised Proceedings of 31st Annual General Meeting
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 452 | 441 | 359 | 428 | 455 | 431 | 281 | 5.0 | 0 | 0 | 0.0 | 0.0 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 410 | 393 | 320 | 385 | 410 | 585 | 343 | 6.0 | 1.9 | 58.5 | 27.7 | 6.7 |
| Operating profit | 42.2 | 48.5 | 39.8 | 43.3 | 44.7 | −154 | −61.9 | −1.0 | −1.9 | −58.5 | −27.7 | −6.7 |
| Operating margin | 9.3% | 11.0% | 11.1% | 10.1% | 9.8% | -35.8% | -22.1% | -20.8% | – | – | -2,77,000.0% | -66,800.0% |
| Other income | 0.5 | 1.5 | 0.6 | 0.7 | 0.6 | 0.1 | 0.4 | 0.7 | 0.7 | 7.6 | 3.4 | 14.1 |
| Interest | 24.8 | 24.2 | 20.0 | 19.8 | 17.1 | 17.7 | 18.7 | 0 | 30.2 | 5.9 | 0.2 | 0 |
| Depreciation | 15.4 | 14.7 | 15.5 | 15.6 | 15.6 | 15.8 | 16.5 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
| Profit before tax | 2.5 | 11.1 | 4.9 | 8.7 | 12.6 | −188 | −96.8 | −0.5 | 56.6 | −56.9 | −24.6 | 7.3 |
| Tax | 0.9 | 10.5 | 2.0 | 3.1 | 4.7 | −57.6 | −33.5 | −0.2 | −11.0 | −19.7 | −8.9 | 3.7 |
| Net profit | 1.6 | 0.6 | 3.0 | 5.6 | 7.8 | −130 | −63.2 | −176 | 14.3 | −67.9 | −15.4 | 2.7 |
| EPS (₹) | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.80 | -2.82 | -7.84 | 0.64 | -3.38 | -0.79 | 0.14 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,783 | 2,367 | 1,544 | 1,669 | 1,525 | 1,686 | 1,673 | 0 |
| Expenses | 2,519 | 2,147 | 1,434 | 1,510 | 1,471 | 1,533 | 1,700 | 60.7 |
| Operating profit | 264 | 220 | 110 | 159 | 54.0 | 153 | −26.5 | −60.7 |
| Operating margin | 9.5% | 9.3% | 7.1% | 9.5% | 3.5% | 9.1% | -1.6% | – |
| Other income | 6.0 | 4.0 | 2.7 | 11.3 | 42.2 | 13.0 | 1.9 | 9.3 |
| Interest | 148 | 126 | 112 | 78.8 | 79.5 | 87.1 | 74.6 | 36.1 |
| Depreciation | 63.3 | 60.8 | 60.3 | 57.0 | 59.1 | 60.7 | 62.4 | 0.3 |
| Profit before tax | 58.8 | 37.5 | −84.8 | 34.1 | −42.4 | 18.3 | −162 | −87.9 |
| Tax | 11.2 | 5.7 | −11.5 | 9.0 | −18.2 | 13.3 | −47.9 | −30.5 |
| Net profit | 47.6 | 31.8 | −73.3 | 25.1 | −24.2 | 5.0 | −114 | −293 |
| EPS (₹) | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.23 | -5.07 | -13.40 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 95.0 | 169 | −349 | 51.3 |
| From investing | 16.6 | −41.9 | 1,208 | −47.7 |
| From financing | −119 | −128 | −767 | −0.2 |
| Spent on fixed assets | −25.0 | −43.8 | −12.3 | −1.2 |
| Free cash flow | 70.0 | 126 | −361 | 50.1 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 1.7% | 1.3% | -4.7% | 1.5% | -1.6% | 0.3% | -6.8% | – |
| Operating margin | 9.5% | 9.3% | 7.1% | 9.5% | 3.5% | 9.1% | -1.6% | – |
| Return on equity | – | – | – | – | -2.3% | 0.5% | -11.9% | -50.3% |
| Return on capital employed | – | – | – | – | 2.0% | 6.2% | -5.7% | -8.9% |
| Return on assets | – | – | – | – | -1.1% | 0.2% | -5.6% | -47.1% |
| Debt to equity | – | – | – | – | 0.71 | 0.59 | 0.61 | 0.00 |
| Interest coverage | 1.40 | 1.30 | 0.20 | 1.40 | 0.50 | 1.20 | -1.20 | -1.40 |
| Debt to assets | – | – | – | – | 0.34 | 0.29 | 0.28 | 0.00 |
| Current ratio | – | – | – | – | 1.38 | 1.32 | 1.21 | 9.71 |
| Quick ratio | – | – | – | – | 0.63 | 0.59 | 0.54 | 9.70 |
| Cash ratio | – | – | – | – | 0.02 | 0.02 | 0.02 | 0.00 |
| Asset turnover | – | – | – | – | 0.70 | 0.77 | 0.82 | – |
| Fixed asset turnover | – | – | – | – | 2.49 | 2.86 | 2.90 | – |
| Inventory turnover | – | – | – | – | – | 1.70 | 2.00 | – |
| Receivables turnover | – | – | – | – | 5.50 | 4.40 | 4.80 | – |
| Gross margin | – | – | – | – | – | 28.7% | 18.2% | – |
| Cash from operations to profit | – | – | – | 379.0% | – | – | – | – |
| Effective tax rate | 19.1% | 15.2% | – | 26.5% | – | 72.7% | – | – |
A copy Srutinizers report of Annual General Meeting held on September 18, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 18, 2026
Please find attached herewith letter sent to the members pursuant to Regulation 36(1)(b)of the SEBI (LODR) Regulations, 2015.
Notice of Annual General Meeting to be held on September 18, 2026
Change in corporate office of the Company
Record date for the purpose of ascertaining the eligibility of members for remote e-voting and/ or polling/ e-voting at 31st AGM is 11-Sep-2026
We wish to inform you that the board of directors of Nectar Lifesciences Limited ( Company ) in their meeting held on August 14, 2026, have, inter-alia, noted, decided and approved the following matters:1. Appointed Dr. Gunmala Suri (DIN: 11879344) as an Additional Director…
The financial results for the period ended Jun 30, 2026.
Resignation of Mr Surulichamy Senthilkumar as Non- Executive Non- Independent Director of the company w.e.f. August 06, 2026.
Sale and Surrender of Leasehold Rights in Land Situated in Jammu